Efficacy and safety of CT‐P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study

• DOI: 10.1111/jgh.12997
• Publication Date: 2015-05-14T09:37:39Z
• Authors: Yoon Suk Jung; Dong Il Park; Young Ho Kim; Ji Hyun Lee; Pyoung Ju Seo; Jae Hee Cheon; Hyoun Woo Kang; Ji Won Kim
• Keywords: Biosimilar

The biosimilar of infliximab, CT-P13, has recently been shown to be equivalent infliximab in both efficacy and safety the treatment rheumatologic diseases. However, no data are available with respect drug's patients inflammatory bowel disease (IBD). We aimed assess CT-P13 IBD patientsThis was a retrospective multicenter study including anti-tumor necrosis factor (TNF) naïve who switched from biologic originator CT-P13.In anti-TNF Crohn's (CD) (n = 32), clinical response remission rates were 90.6% 68.8% at week 2, 84.4% 8, 95.5% 77.3% 30, 87.5% 75.0% 54, respectively. In ulcerative colitis (UC) 42), 76.2% 19.0% 81.0% 38.1% 91.3% 47.8% 100% 50.0% respectively, while mucosal healing 58.3% 66.7% 54. maintained 92.6% (25/27) CD (6/9) UC after switching its originator. Adverse events related occurred 11.8% patients.CT-P13 appears have comparable efficacy, safety, interchangeability IBD. Further prospective studies long-term follow-up periods will needed confirm biosimilarity CT-P13.